I
13.54
-0.10 (-0.73%)
| Previous Close | 13.64 |
| Open | 13.61 |
| Volume | 661,608 |
| Avg. Volume (3M) | 737,439 |
| Market Cap | 886,929,600 |
| Price / Earnings (TTM) | 5.17 |
| Price / Sales | 4.03 |
| Price / Book | 2.10 |
| 52 Weeks Range | |
| Earnings Date | 25 Jul 2023 - 31 Jul 2023 |
| Profit Margin | -16.15% |
| Operating Margin (TTM) | 47.02% |
| Diluted EPS (TTM) | -0.950 |
| Quarterly Revenue Growth (YOY) | 14.40% |
| Quarterly Earnings Growth (YOY) | -67.00% |
| Total Debt/Equity (MRQ) | 80.23% |
| Current Ratio (MRQ) | 2.48 |
| Operating Cash Flow (TTM) | 200.26 M |
| Levered Free Cash Flow (TTM) | 153.81 M |
| Return on Assets (TTM) | 9.40% |
| Return on Equity (TTM) | -8.84% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | Innoviva, Inc. | Bullish | Bullish |
AIStockmoo Score
2.8
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | 5.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 4.0 |
| Average | 2.75 |
|
Innoviva Inc is a company with a portfolio of royalties and innovative healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Ellipta, Trelegy, Ellipta and others. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 0.98% |
| % Held by Institutions | 110.18% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |